Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in Active Surveillance Prostate Cancer
NCT02721979Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Nov 2017
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate adenocarcinoma, sponsored by University of Washington. Primary endpoint: Negative Site Directed and Systematic Prostate Biopsy Rate at 90 days. Started Nov 2017; status: terminated.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT02721979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721979.